Disrupting the immunosuppressive myeloid microenvironment unlocks the next era of cancer immunotherapy

Pablo joined Criteria Bio Ventures in 2018, where he plays a pivotal role in Criteria Bio Ventures' Investment Team, leveraging his extensive experience as a life science investor. He serves as a board director at AbolerIS Pharma, Minoryx Therapeutics, MedLumics, and Aelix Therapeutics, and has held positions on various portfolio company boards including SANIFIT Therapeutics, Splice Bio, iProteos, GlyCardial Diagnostics, and AptaTargets. Before joining Criteria Bio Ventures, Pablo served as Head of the Technology and Business Development Office at the Centre for Genomic Regulation (CRG) from 2013 to 2018. During his tenure, he spearheaded the CRG’s Innovation and Business Strategy, focusing on strategic planning and implementation. Pablo earned his degree in Chemistry from the University of Buenos Aires, followed by a Ph.D. in Organic Chemistry from the University of Barcelona. He conducted postdoctoral research in Synthetic Biology at Harvard Medical School, where he explored new classes of protein-based therapeutics.

Salvatore is a Senior Associate at Criteria Bio Ventures, where he plays a core role in the Investment Team, leveraging his expertise in scouting, analyzing, and building biotech companies. At CBV, he also serves as board director at Adaptam Therapeutics and board observer at MedLumics and Wooptix. Before joining Criteria Bio Ventures, Salvatore was a Business Development Manager at the Centre for Genomic Regulation (CRG) Technology and Business Development Office (TBDO), where he assisted CRG entrepreneurs in assessing business opportunities and structuring their business strategies, leading to successful venture creation. Salvatore holds an MSc in Biomedical Engineering and a PhD in Bioengineering from Politecnico di Milano. His postgraduate credentials include postdoctoral research experience in top-ranking proteomics groups and executive education in science management at IE Business School.

José M is a Board Member at Adaptam Therapeutics. He is the founder and General Director of the Centers CIC bioGUNE in Bilbao and CIC biomaGUNE in San Sebastián, and Research Professor at the Spanish National Research Council (CSIC). José M holds a Ph.D. in Biochemistry from Leiden University, where he was awarded the prestigious CJ Kok prize for his thesis. He completed postdoctoral training at the Biozentrum of the University of Basel and the National Institutes of Health. Throughout his career, José M has held various academic positions, including faculty member at the Jiménez Díaz Foundation in Madrid, Professor at the Faculty of Medicine of the University of Navarra, and Visiting Professor at the University of Pennsylvania and Thomas Jefferson University. From 1992 to 1996, he served as President of the CSIC and was honored with the Spanish National Research Prize in Medicine in 2004.